Soley Therapeutics

Soley Therapeutics is a biotechnology company founded in 2020 as a spinout from the University of California. The company specializes in decoding cellular language at scale using a proprietary AI platform aimed at enhancing drug discovery and development for complex diseases, including oncology, cardiovascular, neurodegenerative, and metabolic diseases. Co-founded by cardiologist Yerem Yeghiazarians and molecular cancer biologist Kurosh Ameri, Soley is dedicated to transforming drug discovery with a focus on patient benefits and values such as scientific rigor and innovation.

The company's core technology includes a high-throughput evaluation platform that utilizes intact human cells for image-based phenotypic screening and AI/ML to model cellular communication and predict cell fate. Soley is actively engaged in drug discovery and development services, producing novel chemical scaffolds and lead candidates, particularly in oncology. Collaborations with Oracle Cloud Infrastructure and NVIDIA enhance its AI capabilities, enabling faster insights for both oncology and non-oncology conditions.